YARW

SEC source: 0001209191-21-013813 · doc4.xml · nonDerivative · entry 1

Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,638

F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc.

F2 · shares: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025.

SEC source: 0001209191-21-013808 · doc4.xml · derivative · entry 2

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 358,750

Underlying: Common Stock · 358,750 shares

Expires 2031-02-22

F2 · derivative.exercise_date: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025.

SEC source: 0001209191-21-013808 · doc4.xml · nonDerivative · entry 1

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 479,833

F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc.

F2 · shares: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025.

SEC source: 0001062993-21-000765 · form4.xml · nonDerivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 27,095,819

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-21-001097 · doc4.xml · nonDerivative · entry 1

Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 357,181

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-001090 · doc4.xml · nonDerivative · entry 1

Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,703

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-001094 · doc4.xml · nonDerivative · entry 1

Stuart Iain · CIK 0001727756 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 286,262

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-001088 · doc4.xml · nonDerivative · entry 1

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,304,334

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-20-061946 · doc4.xml · nonDerivative · entry 1

LEPORE PATRICK G · CIK 0001055404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · kind: Shares purchased pursuant to a 10b5-1 plan.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.69 to $1.735, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-061177 · doc4.xml · nonDerivative · entry 1

Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 358,722

F1 · shares: These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on April 1, 2020 and ending on November 30, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on November 30, 2020 (the last trading day of the offering period). The reporting person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year.

SEC source: 0001209191-20-061175 · doc4.xml · nonDerivative · entry 1

Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 327,525

F1 · shares: These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on April 1, 2020 and ending on November 30, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on November 30, 2020 (the last trading day of the offering period). The reporting person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year.

SEC source: 0001209191-20-061174 · doc4.xml · nonDerivative · entry 1

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,313,990

F1 · shares: These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on April 1, 2020 and ending on November 30, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on November 30, 2020 (the last trading day of the offering period). The reporting person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year.

SEC source: 0001209191-20-053159 · doc4.xml · nonDerivative · entry 1

Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,884

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-20-053157 · doc4.xml · nonDerivative · entry 1

Stuart Iain · CIK 0001727756 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 288,640

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-20-053155 · doc4.xml · nonDerivative · entry 1

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,309,727

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-20-053156 · doc4.xml · nonDerivative · entry 1

Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 317,065

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-20-050292 · doc4.xml · derivative · entry 1

LEPORE PATRICK G · CIK 0001055404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2030-09-10

F1 · derivative.exercise_date: The option will vest and become exercisable as to 1/3rd of the shares subject to the option on each annual anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

SEC source: 0001209191-20-049796 · doc4.xml · nonDerivative · entry 1

Saik Andrew · CIK 0001616284 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 340,000

F1 · price: These shares were purchased in multiple transactions at prices ranging from $1.4499 to $1.4767 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-049795 · doc4.xml · nonDerivative · entry 1

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,315,966

F1 · price: These shares were purchased in multiple transactions at prices ranging from $1.34 to $1.48 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-047960 · doc4.xml · derivative · entry 2

BARBARI SHARON · CIK 0001240499 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,971

Underlying: Common Stock · 75,000 shares

Expires 2029-05-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: These options vested over a 12 month period, in equal, quarterly installments, ending May 16, 2020.

SEC source: 0001209191-20-047960 · doc4.xml · nonDerivative · entry 1

BARBARI SHARON · CIK 0001240499 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-045129 · doc4.xml · derivative · entry 1

Basta Steven L · CIK 0001417397 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2030-08-03

F1 · derivative.exercise_date: These options vest over a 12 month period in equal, quarterly installments, ending August 3, 2021.

SEC source: 0001209191-20-045130 · doc4.xml · derivative · entry 1

Bruno Anthony D · CIK 0001374180 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2030-08-03

F1 · derivative.exercise_date: These options vest over a 12 month period in equal, quarterly installments, ending August 3, 2021.

SEC source: 0001209191-20-045128 · doc4.xml · derivative · entry 1

BARBARI SHARON · CIK 0001240499 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2030-08-03

F1 · derivative.exercise_date: These options vest over a 12 month period in equal, quarterly installments, ending August 3, 2021.

SEC source: 0001209191-20-045135 · doc4.xml · derivative · entry 1

Bright Rex · CIK 0001327501 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2030-08-03

F1 · derivative.exercise_date: These options vest over a 12 month period in equal, quarterly installments, ending August 3, 2021.

SEC source: 0001209191-20-045131 · doc4.xml · derivative · entry 1

Sandoval Elisabeth · CIK 0001632295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2030-08-03

F1 · derivative.exercise_date: These options vest over a 12 month period in equal, quarterly installments, ending August 3, 2021.

SEC source: 0001209191-20-040308 · doc4.xml · nonDerivative · entry 1

Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 352,425

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-20-040303 · doc4.xml · nonDerivative · entry 1

Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 318,887

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-20-040306 · doc4.xml · nonDerivative · entry 1

Stuart Iain · CIK 0001727756 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 291,018

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-20-040293 · doc4.xml · nonDerivative · entry 1

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,240,966

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0000899243-20-016198 · doc4.xml · nonDerivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 22,876,410

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-20-028039 · doc4.xml · derivative · entry 2

Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2030-05-06

F2 · derivative.exercise_date: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024.

SEC source: 0001209191-20-028039 · doc4.xml · nonDerivative · entry 1

Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 353,967

F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo Therapeutics Inc.

F2 · shares: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024.

SEC source: 0001209191-20-028038 · doc4.xml · derivative · entry 2

Stuart Iain · CIK 0001727756 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,500

Underlying: Common Stock · 112,500 shares

Expires 2030-05-06

F2 · derivative.exercise_date: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024.

SEC source: 0001209191-20-028038 · doc4.xml · nonDerivative · entry 1

Stuart Iain · CIK 0001727756 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 293,401

F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo Therapeutics Inc.

F2 · shares: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024.

SEC source: 0001209191-20-028037 · doc4.xml · derivative · entry 2

Saik Andrew · CIK 0001616284 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2030-05-06

F2 · derivative.exercise_date: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024.

SEC source: 0001209191-20-028037 · doc4.xml · nonDerivative · entry 1

Saik Andrew · CIK 0001616284 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo Therapeutics Inc.

F2 · shares: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024.

SEC source: 0001209191-20-028036 · doc4.xml · derivative · entry 2

Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2030-05-06

F2 · derivative.exercise_date: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024.

SEC source: 0001209191-20-028036 · doc4.xml · nonDerivative · entry 1

Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 320,712

F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo Therapeutics Inc.

F2 · shares: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024.

SEC source: 0001209191-20-028034 · doc4.xml · derivative · entry 2

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 680,000

Underlying: Common Stock · 680,000 shares

Expires 2030-05-06

F2 · derivative.exercise_date: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024.

SEC source: 0001209191-20-028034 · doc4.xml · nonDerivative · entry 1

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,247,213

F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo Therapeutics Inc.

F2 · shares: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024.

SEC source: 0001209191-20-023813 · doc4.xml · nonDerivative · entry 3

Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 203,967

F4 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-20-023810 · doc4.xml · nonDerivative · entry 3

Stuart Iain · CIK 0001727756 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,901

F4 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-20-023805 · doc4.xml · nonDerivative · entry 3

Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,712

F4 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-20-023804 · doc4.xml · nonDerivative · entry 3

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 567,213

F4 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-20-023799 · doc4.xml · nonDerivative · entry 1

Basta Steven L · CIK 0001417397 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 536,537

F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares.

SEC source: 0001209191-20-023803 · doc4.xml · nonDerivative · entry 2

Bruno Anthony D · CIK 0001374180 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,056

F3 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo.

F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2)

F2 · price: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing.

SEC source: 0001209191-20-023803 · doc4.xml · nonDerivative · entry 1

Bruno Anthony D · CIK 0001374180 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,123

F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2)

F2 · price: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing.

SEC source: 0001209191-20-023813 · doc4.xml · nonDerivative · entry 2

Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,875

F3 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo.

F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2)

F2 · price: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing.

SEC source: 0001209191-20-023813 · doc4.xml · nonDerivative · entry 1

Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,445

F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2)

F2 · price: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing.